Dr. Sleckman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Harvard Med Sch
Boston, MA 02115
Summary
- Dr. Barry Sleckman completed his MD and PhD (Immunology) at Harvard Medical School in 1990 followed by an internship and residency in Medicine and a fellowship in Infectious Diseases at the Brigham and Women’s Hospital in Boston. In 1998, after completing a post-doctoral fellowship in Molecular Immunology in the laboratory of Dr. Frederick Alt at Harvard Medical School, Dr. Sleckman started his first independent laboratory in the Department of Pathology and Immunology at the Washington University School of Medicine (WUSM) in St. Louis. In 2015 he moved to the Department of Pathology at Weill Cornell Medicine and in 2020 to become the Director of the O’Neal Comprehensive Cancer Center at UAB. His laboratory focuses on elucidating pathways required for immune system development and on understanding DNA damage responses, especially as they apply to cancer and the development of novel cancer therapeutics.
Education & Training
- Harvard Medical SchoolClass of 1989
- Brigham and Women's HospitalResidency, Internal Medicine
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease
Certifications & Licensure
- NY State Medical License 2016 - 2019
- MO State Medical License 2009 - 2017
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2004
Publications & Presentations
PubMed
- 97 citationsDNA double-strand breaks induce H2Ax phosphorylation domains in a contact-dependent mannerPatrick L. Collins, Caitlin E. Purman, Sofia I. Porter, Vincent K. Nganga, Ankita Saini
Nature Communications. 2020-06-22 - 5 citationsLoss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid Development.S. Haihua Chu, Jonathan Chabon, Chloe N. Matovina, Janna Minehart, Bo-Ruei Chen
Iscience. 2020-03-27 - 5 citationsDNA damage responses in murine Pre-B cells with genetic deficiencies in damage response genesCynthia L. Innes, Jill E. Hesse, Abigail J Morales, Beth A. Helmink, Shepherd H. Schurman
Cell Cycle. 2020-01-01
Journal Articles
- Article MRI Is a DNA Damage Response Adaptor During Classical Non-Homologous End JoiningIssa Hindi, David J Pisapia, Barry P Sleckman, ScienceDirect
Press Mentions
- Cancer Disparities Through the DecadesJune 10th, 2022
- O’Neal Comprehensive Cancer Center at UAB Awarded $27.5 Million by National Cancer InstituteJune 9th, 2022
- Breast Cancer Research Foundation of Alabama Exceeds $1.2 Million Investment in Alabama-Based ResearchDecember 3rd, 2021
- Join now to see all
Grant Support
- Localized Revision Of Epigenetic Landscapes Induced By DNA Double-Strand BreaksNational Institute Of Environmental Health Sciences2011–2012
- ATM Function During V(D)J RecombinationNational Institute Of Allergy And Infectious Diseases2009–2012
- Activation Of Cellular Signaling Pathways By DNA Double Strand BreaksNational Cancer Institute2009–2012
- The V(D)J Recombination Reaction And Its Impact On Lymphocyte DevelopmentNational Institute Of Allergy And Infectious Diseases2010–2011
- Regulation Of Tcrbeta Chain Gene RearrangementNational Institute Of Allergy And Infectious Diseases2005–2009
- Regulation Of TCRB Chain Gene RearrangementNational Institute Of Allergy And Infectious Diseases2000–2004
- Regulation Of TCR And LG Gene V To DJ RearrangementNational Institute Of Allergy And Infectious Diseases1994–1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: